Seagen SEAGEN

HealthcareMarket cap $43B1 connection

Seagen pioneered antibody-drug conjugate cancer therapies - precision 'guided missiles' delivering chemotherapy directly to tumor cells. Pfizer acquired it for $43B in 2023, adding four approved ADC drugs and a deep oncology pipeline. ADC technology is now the most promising modality in oncology, generating $4B+ in Pfizer revenue annually and validating one of pharma's largest recent acquisitions.

Explore Seagen on the interactive map Relationship timeline Find a path to another company

Owned by 1

Companies with a stake in Seagen

PfizerHealthcare · $160BPfizer completed $43B Seagen acquisition - ADC oncology expansionsince 2023

Other Healthcare companies

Eli Lilly UnitedHealth Novo Nordisk Johnson & Johnson AbbVie Merck AstraZeneca Thermo Fisher Novartis Abbott Labs

Embed this on your site

Show Seagen's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=SEAGEN" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Seagen on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.